1Chang JT,Chen YL,Yang HT, et al. Differential regulation of telomerase activity by six telomerase subunits[J]. Eur J Biochem,2002,269(14) :3442-3450.
2?AYi X,White DM, Aisner DL, et al. An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity[J]. Neoplasia,2000,2(5) :433-440.?A
3Colgin M, Wilkinson C, Englezou A, et al. The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity[J]. Neoplasia,2000,2(5) :426-432.
4Yang Y, Chen Y, Zhang C, et al. Nucleolar localization of hTERT protein is associated with telomerase function[J]. Exp Cell Res,2002,277(2) :201-209.
5Etheridge KT,Banik SS, Armbruster BN, et al. The nucleolar localization domain of the catalytic subunit of human telomer ase[J]. J Biol Chem,2002,277(27) :24764-24770.
6Bachand F,Triki I,Autexier C. Human telomerase RNA-protein interaction [J ]. Nucleic Acids Res, 2001,29 (16): 3385-3393.
7Braunstein I, Cohen-Barak O,Shachaf C, et al. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cell[J]. Cancer Res, 2001,61 (14): 5529 -5536.
8Majumdar AS, Hughes DE, Lichtsteiner SP,et al. The telomerase reverse transcriptase promoter drives efficacious tumorsuicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters[J]. Gene Ther, 2001, 8(7):568-578.
9Braunstein I, Cohen-Barak O, Shachaf C,et al. Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells[J]. Cancer Res, 2001,61 (14): 5529-5536.
10Gu J, Kagawa S, Takakura M, et al. Tumor-specific trans gene expression from the human telomerase reverse transcriptase promoter enables targeting of the therapeutic effects of the Bax gene to cancers[J]. Cancer Res, 2000, 60 (19):5359-5364.
4Nettelbeck DM, Jerome V, Muller R. Gene therapy: designer promoters for tumour targeting[ J]. Trends Genet, 2000,16(4) :174.
5Freeman BC, Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones[J]. Science, 2002,296 ( 5576 ) : 2232-2235.
6Xiaofeng Wang, Xiaomin Song,Wei Zhuo, et al. The regulatory mechanism of HSP90 secretion and its function in tumor malignancy[J]. Proc Natl Acad Sci USA,2009, 106 ( 50 ) : 21288-93.
7Anjian Xu, Tian Tian, Jia Hao,et al. Elevation of Serum HSP90 α Correlated with the Clinical Stage of Non-Small Cell Lung Cancer[J].J Cancer Mol, 2007,3 ( 4 ) : 107-112.
8Flora Zagouri, Theodoros N.Sergentanis, Xeni Provato Poulou, et al. Serum Levels of HSP90 in the Continuum of Breast Ductal and Lobular Lesions[J].In Vivo, 2011,25 ( 4 ) : 669-672.
9Oxelmark E, Roth JM, Brooks PC, et al. The cochaperone P23 differentially regulates estrogen receptor target genes and Promotes tumor cell adhesion and invasion[J].Mol Cell Biol,2006 ( 26 ): 5205-13.
10Forafonov F, Toogun OA, Grad I, et al.P23/SbalP protects against HSP90 inhibitors independently of its intrinsic chaperone activity[J].Mol Cell Biol, 2008 ( 28 ) : 3446-56.
